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Trial Design

The cVAD registry for percutaneous temporary
hemodynamic support: A prospective registry
of Impella mechanical circulatory support use
in high-risk PCI, cardiogenic shock, and
decompensated heart failure
George W. Vetrovec, MD, a Mark Anderson, MD, b Theodore Schreiber, MD, c Jeffrey Popma, MD, d
William Lombardi, MD, e Brijeshwar Maini, MD, f Jacob Eifer Moller, MD, g Andreas Schäfer, MD, h Simon R. Dixon, MBChB, i
Shelley Hall, MD, j E. Magnus Ohman, MD, k Catalin Mindrescu, MD, l Jeffrey Moses, MD, m and William O'Neill, MD n
Richmond, VA; Philadelphia, PA; Detroit, Royal Oak, MI; Boston, Danvers, MA; Seattle, WA; Delray, FL; Odense, Denmark;
Hanover, Germany; Dallas, TX; Durham, NC; and New York, NY

Management of patients requiring temporary, mechanical hemodynamic support during high- risk percutaneous coronary
intervention (PCI) or in cardiogenic shock is rapidly evolving. With the availability of the Impella 2.5, CP, 5.0, LD, and RP
percutaneous mechanical circulatory support devices, there is a need for continued surveillance of outcomes.
Three factors underline the importance of a registry for these populations. First, large randomized trials of hemodynamic
support, involving cardiogenic shock, are challenging to conduct. Second, there is increasing interest in the use of registries to
provide “real-world” experience and to allow the flexibility to evaluate individual patient uses and outcomes. Third, current,
large databases have not captured the specific impact of mechanical support treatment of cardiogenic shock.
The predecessor to the catheter-based ventricular assist devices registry, known as USpella, began in 2009 with paper data
acquisition but beginning in 2011 transferred to electronic data capture, enrolling 3,339 patients through 2016. Throughout,
registry data have been used to assess the outcomes of Impella therapy, leading to 8 publications and 4 Food and Drug
Administration premarket approvals covering multiple indications and Impella devices.
Going forward, the registry will continue to assess not only in-hospital outcomes but long-term follow-up to 1 year. In addition,
data management will be enhanced to assess quality and clinical experiences. The registry will also provide a mechanism for
postmarketing surveillance.
This manuscript reviews the ongoing catheter-based ventricular assist devices registry design, management, and contributions
of the registry data. The upgraded registry will provide a more robust opportunity to assess acute and late outcomes of current
and future device use worldwide.
Condensed abstract The current catheter-based ventricular assist devices registry is an international database
documenting outcomes with temporary Impella hemodynamic support. The registry has supported 8 publications and 4 Food
and Drug Administration premarket approvals since its inception in 2009. The current registry is more robust containing
outcomes up to 1 year postprocedure. (Am Heart J 2018;199:115-21.)

Device registries are a growing method to obtain
“real-world” outcome data to define quality metrics and
to document acute and late outcomes of new devices to

assure predicted outcomes while providing an opportunity to evaluate potential new applications of evolving
innovative technology. 1 The catheter-based ventricular
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assist devices (cVAD) registry is an expanded but
continuing registry for the evaluation of Impella mechanical circulatory support (MCS) used in the management of
patients undergoing high-risk percutaneous coronary
intervention (PCI) and patients presenting with cardiogenic shock of various etiologies such as acute myocardial infarction (AMI), post open-heart surgery,
myocarditis, cardiomyopathies, and arrhythmias, or for
severe heart failure requiring hemodynamic support in
the setting acute or chronic cardiac dysfunction.
Impella hemodynamic support devices represent an
evolving series of mechanical circulatory devices designed to support both sides of the heart. The left-sided
Impella devices include Impella 2.5, Impella CP, Impella
5.0, and Impella LD and were designed to support the left
ventricle. The Impella RP is designed to support the right
ventricle. The Impella devices are the smallest and least
invasive percutaneous ventricular support blood pumps
available on the market. The left-sided devices directly
unload the left ventricle and propel blood forward, from
the left ventricle into the aorta, in a manner consistent
with normal physiology. 2,3 Depending on the size of the
device, they provide a blood flow ranging from 2.5 to 5 L/
min. This results in an increase in mean arterial blood
pressure, cardiac output, and coronary flow while
“unloading” left ventricular filling pressures to reduce
myocardial oxygen demand.” 4-6 The right-sided device,
Impella RP, unloads the right ventricle and reduces the
central venous pressure, allowing increased pulmonary
venous return to the left heart. The Impella RP can provide
up to 4 L/min of blood flow from the inferior vena cava into
the pulmonary artery. 7 The uniqueness of such evolving
and innovative therapy is ideal for a registry where the
application in a variety of clinical scenarios provides an
opportunity to ensure efficacy and quality with an
opportunity to evaluate physician-initiated expanded uses
for the Impella hemodynamic support system.
The value of a registry for ongoing evaluation of a new
therapeutic device is emphasized by the recent evaluation of transcatheter aortic valve replacement via the
combined Society of Thoracic Surgeons–American College of Cardiology (ACC) transcatheter valve therapy
(TVT) national registry. 8,9 That study has combined the
efforts of the ACC and the Society of Thoracic Surgeons,
with a history of major quality outcome procedure
registries. However, in the case of hemodynamic support,
the importance of an independent Impella registry is
emphasized by the fact that, to date, the ACC National
Cardiovascular Data Registry (NCDR) PCI registry has not
included specific support device types or distinctive data
acquisition for this specialized population to the detail
that can be obtained by a specific, dedicated registry
similar to the TVT Registry. The INTERMACS registry has
created an infrastructure for data collection related to the
durable ventricular assist devices (VADs) and contributed
to the advancement of the field of mechanical circulatory
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support. 10,11 However, data collection is not comprehensive and is mostly limited to surgically implantable VADs.
The cVAD registry will fill the gap and will provide more
granularity which will allow a better characterization of
patients supported with percutaneous temporary VADs.
Although there is much discussion about the value of “big
data” 12 collections, smaller registries in contrast have
significant merit to evaluate more diverse, limited populations with unique characteristics that would be impossible
to randomize and if done would focus on only a few
specific end points, thus losing learning achieved from
reporting the evolving uses of a device. The value of
registry data to track device outcomes has been recently
cited by Resnic et al 13 who reported using NCDR data to
assess vascular closure device outcomes. The accompanying editorial by Resar and Wiesfeldt 14 points out the
importance of careful data analysis in drawing conclusions.
The Impella cVAD registry provides these specific benefits.
The goal of this manuscript is to describe the history,
clinical impact, and regulatory advantages of the original
and recently expanded cVAD registry, focusing on
demonstrating optimum clinical outcomes of Impella
hemodynamic support for patients with acute and/or
chronically compromised cardiac function.

History of original Impella registry
The initial Impella registry (USpella) was an
investigator-initiated registry started in 2009 after initial
United States Food and Drug Administration (FDA)
approval of the Impella 2.5 in 2008. Initial enrollment
included sites that had performed at least 4 unselected
cases and agreed to enter all patients after obtaining local
institutional review board approval for participation in
the Impella registry. The initial report in 2012 that
described the use of the Impella 2.5 in patients
undergoing high-risk PCI comprised 175 patients from
18 centers. 15 It was termed the USpella registry. By 2013,
the USpella registry had grown to incorporate the Impella
2.5, CP, and 5.0 devices and included N1,300 patients.
Subsequently, the registry has continued to grow. By the
end of 2015, a total of 2,873 patients have been enrolled
from 59 centers. After that time, the database was converted
to the cVAD registry that continued to enroll patients to a
total of 3,339 by the end of 2016 using a retrospective
design (Figure 1). Starting in 2017, the registry design
became prospective as described in the section below.
Since its inception to today, high- and low-volume sites,
academic (teaching) and nonacademic institutions, and
centers with or without on-site transplant program have
participated in the registry, providing a good representation of clinical practice (Table I).
Deidentified patient data were initially extracted from
patient medical records, but since 2012, all data have
been collected using an electronic case report form with
an electronic data capturing system. To maintain
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Table I. Characteristics and complexity of the registry
participating sites
Site characteristic

Patient enrollment by year in Impella registry (USpella and cVAD).

consistency and to allow for study results comparability,
adverse event definitions in the USpella registry have
been consistent with those used in the PROTECT II trial 5
and RECOVER I trial. 3 Reported data have been
compared with source documentation in the majority
of cases based on available records. Abiomed Inc has
provided and continues funding of the data management.

Accomplishments of the USpella registry
The USpella registry has provided significant published
data regarding the use of Impella mechanical circulatory
support in patients undergoing high-risk PCI, PCI for AMI
with cardiogenic shock, postcardiotomy cardiogenic
shock, as well as very specialized uses such as support
for acute and decompensated cardiomyopathies. A
summary of these studies is provided in Table II.
In addition, the database has been used for regulatory
approval of new and expanding premarket approval (PMA)–
based US FDA approvals of new devices and indications.
Table III summarizes the successful regulatory approvals.

The cVAD registry
The global cVAD registry has replaced the USpella
registry but continues as an observational, multicenter
registry of patients receiving Impella devices in the daily,
routine clinical care per institutional standards and
treating physician's discretion. However, the new registry provides longer-term follow-up complying with
regulatory needs post PMA approvals noted in Table II.
FDA-mandated postapproval studies nested within the
registry allows the sponsor to use this infrastructure to
meet its condition of approval requirements.
The cVAD registry is open to all centers provided that
they meet the site selection criteria. General site selection
criteria are based on device utilization, research infrastructure available at a center, and the interest of a center
to participate. Efforts will continue to include as many as

No. of beds
b250
250-500
501-750
751-1000
N1000
Academic
Transplant program
Location: urban
Location by geography
USA
International
PCI annual volume⁎
Low (b400)
Intermediate (400-800)
High (N800)

% (n)

6% (5)
32% (28)
27% (24)
23% (20)
12% (10)
67% (59)
47% (41)
98% (86)
84% (74)
16% (14)
39% (28)
46% (33)
15% (11)

n, Number of centers.
⁎ Data available only for USA.

feasible based on the criteria and considerations described. There is no charge to participate in the registry.
Sites are compensated for the administrative effort to
report their data.
The registry now includes significant global participation with inclusion of United States, Canada, Germany,
Great Britain, Spain, France, Netherlands, and Switzerland and anticipated future international sites including
Japan, Denmark, and Italy (Figure 2). Entry continues to
emphasize sequential patients without preselection.
Feedback is provided to the sites from the manufacturer
to ensure capture of device use at each center. With the
current design, patients in each center will be enrolled
prospectively. Data pertaining to the index hospitalization (admission through discharge) and after patient's
discharge up to 1 year post Impella implant date will be
collected for this registry. The index hospitalization is the
hospitalization when the patient received or had
attempted an insertion of an Impella device.
To collect unbiased and accurate in-hospital data, a
waiver of informed consent and authorization will be
requested for all patients. This will not impact the
patients' rights and welfare, as they will receive the
customary care without any alteration. To collect the
postdischarge data, all patients who were discharged
alive from the index hospitalization will be followed up
by telephone contact up to 1 year after the Impella
implant. Collected variables include only the physician-directed clinical care and phone follow-up. Data elements
collected are shown in Table IV. Patients are not
subjected to any testing or treatment related to registry
inclusion. Once enrolled, each patient will remain in the
registry until the required 1-year follow-up period is
complete. Posthospitalization telephone contact is scheduled as noted in Table V. Institutional Review Board or
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Table II. USpella/cVAD registry publications
Title

Authors

Patients
(n)

Catheter Cardiovasc Interv.
2012; 80: 717-25

175

The current use of Impella 2.5 in AMI O'Neill W.W., Schreiber T.,
complicated by cardiogenic shock: Wohns D.H., Rihal C.,
results from the USpella Registry 17 Naidu S.S., Civitello A.B.,
Dixon S.R., Massaro J.M.,
Maini B., Ohman E.M.
Percutaneous left ventricular assist
Cohen M.G., Matthews R.,
device for high-risk percutaneous
Maini B., Dixon S.,
coronary interventions: real-world Vetrovec G., Wohns D.,
versus clinical trial experience21
Palacios I., Popma J.,
Ohman E.M., Schreiber T.,
O'Neill W.W.

J Interv Cardiol. 2014:
27:1-11

154

Am Heart J. 2015 Nov;
170: 872-9

637

Effectiveness and Safety of the Impella
5.0 as a bridge to cardiac
transplantation or durable left
ventricular assist device22

Lima B., Kale P.,
Gonzalez-Stawinski G.V.,
Kuiper J.J., Carey S.,
Hall S.A.

Am J Cardiol. 2016:15;
117:1622-8

40

Women with cardiogenic shock
derive greater benefit from early
mechanical circulatory support: an
update from the cVAD registry23

Joseph S.M., Brisco M.A.,
Colvin M., Grady K.L.,
Walsh M.N., Cook J.L.

J Interv Cardiol. 2016; 29:
248-56

180

Effect of early initiation of
mechanical circulatory support on
survival in cardiogenic shock16

Basir M.B., Schreiber T.L.,
Grines C.L., Dixon S.R.,
Moses J.W., Maini B.S.,
Khandelwal A.K.,
Ohman E.M., O'Neill W.W.
Meraj P.M., Schreiber T.L.,
Maini B.S., O'Neill W.W.

Am J Cardiol. 2016 Dec 18.
pii: S0002-9149(16)31937-3.

287

Real-world use of the Impella 2.5
circulatory support system in
complex high-risk percutaneous
coronary intervention: the USpella
Registry 15

Impella 2.5 initiated prior to
unprotected left main PCI in acute
myocardial infarction complicated
by cardiogenic shock improves
survival24
Real-world supported unprotected
left main percutaneous coronary
intervention with Impella device;
data from the USpella registry25

Maini B., Naidu S.S.,
Mulukutla S., Kleiman N.,
Schreiber T., Wohns D.,
Dixon S., Rihal C., Dave R.,
O'Neill W.

Journal

J Interv Cardiol. 2017;
accepted manuscript

Schreiber T., Wah Htun W.,
Catheter Cardiovasc Interv.
Blank N., Telila T., Mercado N., 2017, accepted manuscript
Briasoulis A., Kaki A.,
Kondur A., Munir A., Grines C.

36

127

Clinical conclusions
The use of Impella 2.5 in high-risk PCI
appeared feasible and safe in the
real-world setting. Utilization of the
Impella 2.5 was successful, resulting
in favorable short- and midterm
angiographic, procedural, and
clinical outcomes.
Study supports early initiation of
hemodynamic support prior to PCI with
Impella 2.5 in the setting of CS in AMI
allowing more complete revascularization
and improved survival.
USpella provides a real-world description
of procedures and outcomes for high-risk
patients undergoing PCI supported by
Impella 2.5. Despite higher risk for registry
patients, clinical outcomes appeared
favorable and consistent with the
randomized trial data.
Temporary support with the Impella 5.0
provides an effective “bridge to decision”
strategy for hemodynamic stabilization
of critically ill patients with heart failure.
Consequently, many of these patients were
successfully bridged to the next therapy
with favorable outcomes.
Early initiation of hemodynamic support
prior to PCI with Impella 2.5, in the
setting of AMI complicated by CS, was
associated with a greater survival benefit
to hospital discharge in women compared
with men despite a higher predicted risk
of mortality and a greater revascularization
failure rate for women.
MCS implantation early after shock onset,
before initiation of inotropes or vasopressors
and before PCI, is independently associated
with improved survival in patients presenting
with AMICS.
Initiation of Impella 2.5 pLVAD prior to the
start of a PCI on an ULMCA culprit lesion is
associated with significant survival benefit
in patients supported for AMICS. Patients
supported after the start of the PCI appear to
have very poor survival at 30 d.
This large singe-center retrospective
evaluation of USpella registry substantiates
and strongly supports the feasibility, safety,
and hemodynamic usefulness of Impella
device for ULMI with acceptable in-hospital
and 30-d MACE rates.

CS, Cardiogenic shock.

Independent Ethics Committee approval for the protocol
and informed consent will be obtained by investigator prior
to registry initiation and maintained throughout the duration
of site participation in the registry. This provides preservation of the patient's rights and welfare while ensuring a
scientifically sound acute and late registry data set.

A Steering Committee composed of internationally
recognized investigators and experts in the field of
interventional cardiology, cardiovascular surgery, cardiac
electrophysiology, heart failure, and mechanical circulatory support has been established to provide technical
and scientific oversight of the registry. The Steering
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Table III. USpella regulatory results
Submission type and number
PMA;
PMA;
PMA;
PMA;

P140003
P140003-S005
P140003-S004
P140003-S008

Notice date

Devices

Indication

04/10/2015
05/11/2016
07/05/2016
12/01/2016

2.5
2.5, CP, 5.0, LD
2.5, CP, 5.0, LD
CP

High-risk PCI
AMI-CS
PCCS
High-risk PCI

Figure 2

Worldwide participation in the cVAD registry by country.

Committee and the Sponsor may appoint other independent committees to resolve specific problems such as
verifying patient classification, adverse events adjudication, or publication policy. In addition, there is a Board of
Directors comprised of 3 members of the Executive
Committee who are available for immediate decisions
that may arise.
To provide consistent and unbiased data analysis, the
cVAD registry will use independent analytic Core Laboratories: Angiographic Core Laboratory of Harvard Medical
Faculty Physicians at Beth Israel Deaconess Medical Center,
Inc., and Yale Echocardiographic Core Laboratory. Echocardiographic and angiographic image acquisition is being
managed by Medidata Medical Imaging. An independent
Clinical Events Committee will adjudicate the site-reported
major adverse cardiac and cerebrovascular events accord-

ing to the registry definitions, and their relatedness to the
device and procedure.
A major goal is to use the database to reaffirm concepts
and to expand the understanding of the clinical science of
hemodynamic support. To this end, the cVAD registry is
to provide each participating center with their results for
internal use in documenting quality and local outcomes.
In addition, sites will be encouraged to develop
hypotheses for analyses from the full registry database
for potential publication. Targets for analysis will focus on
improving outcomes and quality of care. Specifically,
assessments of morbidity and mortality, need for MCS,
timing of device insertion, size of device (extent of
support) as well as optimal duration of therapy are all
opportunities to expand the appropriate use and
understanding of the role of hemodynamic support.
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Table IV. cVAD Registry data elements, analysis, and reporting
• Deidentified basic demographics, vital signs, risk factors, medical
and cardiac history
• Hospital admission/discharge information and hospital coding
• Patient hospital course and procedures
• Impella support information
• Hemodynamic parameters
• Angiographic and echocardiographic data
• Hematology and blood chemistry laboratory assessments
• Medications
• Patient status information; in-hospital, 30-d, 90-d, and 1-y
outcomes
• Adverse events
• Harmonization of elements and definitions with national and
international registries, pivotal trials, and consensus groups
whenever possible.
• Participating sites responsible for data entry using web-based data
entry interface on registry specific electronic Case Report Forms
and entered into a controlled 21 CFR Part 11 compliant Electronic
Data Capture System.
• Completeness and accuracy of data entry monitored and audited
both internally and externally.
• Protection of confidential health care information and utilization
of patient informed consent when appropriate.
• Periodic benchmarking reports for sites to compare the institution's performance with that of volume-based peer groups and the
national and international experience.
• Regular interval scientific publication reporting of overall demographic and outcome data in addition to special, device or/or
novel use experience.

Database requests are limited to the registry sites and
must be approved by the steering committee.

Summary
The intent of the global cVAD registry is to provide a
data repository and reporting infrastructure for the
surveillance of the Impella devices in real-world settings,
to serve as a tool to measure and improve the quality of
patient care, and to serve as a resource for future research
and regulatory filings. The cVAD registry is a unique and
modern registry specifically providing insights into a
rapidly evolving Impella hemodynamic technology increasingly used in a variety of applications. In addition,
the registry provides an excellent method to acquire
FDA-mandated postmarketing surveillance while providing
an opportunity to introduce data acquisition for new
technology such as the Impella RP, a right ventricular
support device currently under a special Humanitarian
Device Exemption approval, and its evolving designs.
Beyond these specific regulatory issues, there are opportunities to assess “orphan” uses in specialized populations
such as myocarditis, peripartum cardiomyopathy, and
other cardiomyopathies requiring transient hemodynamic
support. Furthermore, the cVAD registry structure is such
that data acquisition is independent and source documented while providing later follow-up, all of which are unique
and often not available for larger databases.

Table V. Postdischarge patient follow-up schedule
Follow-up time point
30 d
90 d
1y

± Days window

Type of visit

10
14
30

Telephone contact
Telephone contact
Telephone contact

Beyond specific regulatory goals of assessing cardiac
hemodynamic support using a series of specific and
increasingly refined devices, the cVAD registry provides
beneficial “real-world” outcome and quality data. The
latter continues to be a critical opportunity to provide
outcome data to support clinical decision making and
care recommendations. Examples include data demonstrating the benefit of earlier support in the setting of
AMICS to achieve improved outcomes. 16,17 Increasingly,
available data will continue to influence and clarify
published clinical practice, guideline, and care algorithms
going forward such as those currently available in the
United States 18 and Europe. 19 In addition, regular
publications of overall registry experience will inform
the clinical environment of the changes in clinical
practice and outcomes over time. This mirrors what has
been effectively achieved by the NCDR regarding more
global results of PCI outcomes. 20 Lastly, the addition of
international outcomes into the database will potentially
allow an opportunity to develop optimal methods and
uses by better understanding the unique strategies
adopted in diverse practice environments.
Because the registry is industry sponsored, it would be
impossible to acquire information regarding other
devices. Furthermore, Impella devices are currently the
only percutaneous mechanical circulatory support devices approved for specific clinical indications, and thus,
the registry was designed to include only Impella family
of devices. In the future, through a partnership with a
professional society that would provide the registry
management and oversight, the registry could be
modified to accommodate all percutaneous and surgical
mechanical circulatory support devices. Links to NCDR
databases or other longitudinal databases could be
established.
In summary, the cVAD registry will provide an
expanded evaluation of new device technology and
uses within the framework of varied and potentially
expanding clinical experience.
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